Acetylome and phosphoproteome modifications in imatinib resistant chronic myeloid leukaemia cells treated with valproic acid

Leukemia Research

Volumn 35, Issue 7, 2011, Pages 921-931

  Buchi, Francesca ^a   Pastorelli, Roberta ^a   Ferrari, Germano ^a   Spinelli, Elena ^a   Gozzini, Antonella ^a   Sassolini, Francesca ^a   Bosi, Alberto ^a   Tombaccini, Donatella ^a   Santini, Valeria ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

CML BCR ABL; Imatinib resistance; Protein acetylation; Protein phosphorylation; Proteomics; Valproic acid

Indexed keywords

ACETYLOME; HEAT SHOCK PROTEIN 90; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN L; IMATINIB; PHOSPHOPROTEOME; PROTEOME; UNCLASSIFIED DRUG; VALPROIC ACID;

ACETYLATION; APOPTOSIS; ARTICLE; CELL VIABILITY; CHRONIC MYELOID LEUKEMIA; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG RESISTANCE; DRUG SENSITIVITY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; LEUKEMIA CELL; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN MODIFICATION; PROTEIN PHOSPHORYLATION; TWO DIMENSIONAL ELECTROPHORESIS;

ACETYLATION; APOPTOSIS; BLOTTING, WESTERN; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; FUSION PROTEINS, BCR-ABL; HISTONE DEACETYLASE INHIBITORS; HUMANS; IMMUNOPRECIPITATION; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PHOSPHOTYROSINE; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTEOME; PYRIMIDINES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TUMOR CELLS, CULTURED; VALPROIC ACID;

EID: 79958755338     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2011.01.033     Document Type: Article

References (44)

1. Gambacorti-Passerini C.B., Gunby R.H., Piazza R., Galietta A., Rostagno R., Scapozza L. Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias. Lancet Oncol 2003, 4:75-85.
2. Kantarjian H.M., Talpaz M., Giles F., O'Brien S., Cortes J. New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance. Ann Intern Med 2006, 145:913-923.
3. Jabbour E., Cortes J.E., Ghanem H., O'Brien S., Kantarjian H.M. Targeted therapy in chronic myeloid leukemia. Expert Rev Anticancer Ther 2008, 8:99-110.
4. Nimmanapalli R., Fuino L., Bali P., Gasparetto M., Glozak M., Tao J., et al. Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells. Cancer Res 2003, 63:5126-5135.
5. Nimmanapalli R., Fuino L., Stobaugh C., Richon V., Bhalla K. Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells. Blood 2003, 101:3236-3239.
6. Peng C., Brain J., Hu Y., Goodrich A., Kong L., Grayzel D., et al. Inhibition of heat shock protein 90 prolongs survival of mice with BCR-ABL-T315I-induced leukemia and suppresses leukemic stem cells. Blood 2007, 110:678-685.
7. Solit D.B., Ivy S.P., Kopil C., Sikorski R., Morris M.J., Slovin S.F., et al. Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. Clin Cancer Res 2007, 13:1775-1782.
8. Guo F., Rocha K., Bali P., Pranpat M., Fiskus W., Boyapalle S., et al. Abrogation of heat shock protein 70 induction as a strategy to increase antileukemia activity of heat shock protein 90 inhibitor 17-allylamino-demethoxy geldanamycin. Cancer Res 2005, 65:10536-10544.
9. Bali P., Pranpat M., Bradner J., Balasis M., Fiskus W., Guo F., et al. Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors. J Biol Chem 2005, 280:26729-26734.
10. Radujkovic A., Schad M., Topaly J., Veldwijk M.R., Laufs S., Schultheis B.S., et al. Synergistic activity of imatinib and 17-AAG in imatinib-resistant CML cells overexpressing BCR-ABL-inhibition of P-glycoprotein function by 17-AAG. Leukemia 2005, 19:1198-1206.
11. Peng C., Li D., Li S. Heat shock protein 90: a potential therapeutic target in leukemic progenitor and stem cells harboring mutant BCR-ABL resistant to kinase inhibitors. Cell Cycle 2007, 6:2227-2231.
12. Santini V., Gozzini A., Ferrari G. Histone deacetylase inhibitors: molecular and biological activity as a premise to clinical application. Curr Drug Metab 2007, 8:383-393.
13. Lane A.A., Chabner B.A. Histone deacetylase inhibitors in cancer therapy. J Clin Oncol 2009, 27:5459-5468.
14. Fiskus W., Pranpat M., Balasis M., Bali P., Estrella V., Kumaraswamy S., et al. Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells. Clin Cancer Res 2006, 12:5869-5878.
15. Xu Y., Voelter-Mahlknecht S., Mahlknecht U. The histone deacetylase inhibitor suberoylanilide hydroxamic acid down-regulates expression levels of Bcr-abl, c-Myc and HDAC3 in chronic myeloid leukemia cell lines. Int J Mol Med 2005, 15:169-172.
16. Ferrari G., Pastorelli R., Buchi F., Spinelli E., Gozzini A., Bosi A., et al. Comparative proteomic analysis of chronic myelogenous leukemia cells: inside the mechanism of imatinib resistance. J Proteome Res 2007, 6:367-375.
17. Kircher B., Schumacher P., Petzer A., Hoflehner E., Haun M., Wolf A.M., et al. Anti-leukemic activity of valproic acid and imatinib mesylate on human Ph+ ALL and CML cells in vitro. Eur J Haematol 2009, 83:48-56.
18. Morotti A., Cilloni D., Messa F., Arruga F., Defilippi I., Carturan S., et al. Valproate enhances imatinib-induced growth arrest and apoptosis in chronic myeloid leukemia cells. Cancer 2006, 106:1188-1196.
19. Navakauskiene R., Treigyte G., Gineitis A., Magnusson K.E. Identification of apoptotic tyrosine-phosphorylated proteins after etoposide or retinoic acid treatment. Proteomics 2004, 4:1029-1041.
20. Gambacorti-Passerini C., le Coutre P., Mologni L., Fanelli M., Bertazzoli C., Marchesi E., et al. Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis. Blood Cells Mol Dis 1997, 23:380-394.
21. Seigneurin D., Champelovier P., Mouchiroud G., Berthier R., Leroux D., Prenant M., et al. Human chronic myeloid leukemic cell line with positive Philadelphia chromosome exhibits megakaryocytic and erythroid characteristics. Exp Hematol 1987, 15:822-832.
22. Beran M., Pisa P., O'Brien S., Kurzrock R., Siciliano M., Cork A., et al. Biological properties and growth in SCID mice of a new myelogenous leukemia cell line (KBM-5) derived from chronic myelogenous leukemia cells in the blastic phase. Cancer Res 1993, 53:3603-3610.
23. Mahon F.X., Deininger M.W., Schultheis B., Chabrol J., Reiffers J., Goldman J.M., et al. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood 2000, 96:1070-1079.
24. Ricci C., Scappini B., Divoky V., Gatto S., Onida F., Verstovsek S., et al. Mutation in the ATP-binding pocket of the ABL kinase domain in an STI571-resistant BCR/ABL-positive cell line. Cancer Res 2002, 62:5995-5998.
25. Bug G., Gul H., Schwarz K., Pfeifer H., Kampfmann M., Zheng X., et al. Valproic acid stimulates proliferation and self-renewal of hematopoietic stem cells. Cancer Res 2005, 65:2537-2541.
26. Molloy M.P., Phadke N.D., Maddock J.R., Andrews P.C. Two-dimensional electrophoresis and peptide mass fingerprinting of bacterial outer membrane proteins. Electrophoresis 2001, 22:1686-1696.
27. Huang D., Liu X., Plymate S.R., Idowu M., Grimes M., Best A.M., et al. Proteomic identification of 14-3-3 sigma as a common component of the androgen receptor and the epidermal growth factor receptor signaling pathways of the human prostate epithelial cell line M12. Oncogene 2004, 23:6881-6889.
28. Tipping A.J., Mahon F.X., Lagarde V., Goldman J.M., Melo J.V. Restoration of sensitivity to STI571 in STI571-resistant chronic myeloid leukemia cells. Blood 2001, 98:3864-3867.
29. Steinberg M. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia. Clin Ther 2007, 29:2289-2308.
30. Jabbour E., Cortes J., O'Brien S., Giles F., Kantarjian H. New targeted therapies for chronic myelogenous leukemia: opportunities to overcome imatinib resistance. Semin Hematol 2007, 44:S25-31.
31. Gambacorti-Passerini C., Dong-Wook Kim, Kantarjian H., Brummendorf T.H., Dyagil I., Griskevicius L., et al. An ongoing phase 3 study of bosutinib (SKI-606) versus imatinib in patients with newly diagnosed chronic phase chronic myeloid leukemia. Blood (ASH Annual Meeting Abstracts) 2010, 116:208.
32. Hantschel O., Wiesner S., Guttler T., Mackereth C.D., Rix L.L., Mikes Z., et al. Structural basis for the cytoskeletal association of Bcr-Abl/c-Abl. Mol Cell 2005, 19:461-473.
33. Wolanin K., Magalska A., Kusio-Kobialka M., Podszywalow-Bartnicka P., Vejda S., McKenna S.L., et al. Expression of oncogenic kinase Bcr-Abl impairs mitotic checkpoint and promotes aberrant divisions and resistance to microtubule-targeting agents. Mol Cancer Ther 2010, 9:1328-1338.
34. Gleixner K.V., Ferenc V., Peter B., Gruze A., Meyer R.A., Hadzijusufovic E., et al. Polo-like kinase 1 (Plk1) as a novel drug target in chronic myeloid leukemia: overriding imatinib resistance with the Plk1 inhibitor BI 2536. Cancer Res 2010, 70:1513-1523.
35. Fontana S., Alessandro R., Barranca M., Giordano M., Corrado C., Zanella-Cleon I., et al. Comparative proteome profiling and functional analysis of chronic myelogenous leukemia cell lines. J Proteome Res 2007, 6:4330-4342.
36. Pizzatti L., Sa L.A., de Souza J.M., Bisch P.M., Abdelhay E. Altered protein profile in chronic myeloid leukemia chronic phase identified by a comparative proteomic study. Biochim Biophys Acta 2006, 1764:929-942.
37. Grebenova D., Kuzelova K., Pluskalova M., Peslova G., Halada P., Hrkal Z. The proteomic study of sodium butyrate antiproliferative/cytodifferentiation effects on K562 cells. Blood Cells Mol Dis 2006, 37:210-217.
38. Gatto S., Scappini B., Pham L., Onida F., Milella M., Ball G., et al. The proteasome inhibitor PS-341 inhibits growth and induces apoptosis in Bcr/Abl-positive cell lines sensitive and resistant to imatinib mesylate. Haematologica 2003, 88:853-863.
39. Baccarani M., Martinelli G., Rosti G., Trabacchi E., Testoni N., Bassi S., et al. Imatinib and pegylated human recombinant interferon-alpha2b in early chronic-phase chronic myeloid leukemia. Blood 2004, 104:4245-4251.
40. Fiskus W., Pranpat M., Bali P., Balasis M., Kumaraswamy S., Boyapalle S., et al. Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against Bcr-Abl-expressing human leukemia cells. Blood 2006, 108:645-652.
41. Lee S.M., Bae J.H., Kim M.J., Lee H.S., Lee M.K., Chung B.S., et al. Bcr-Abl-independent imatinib-resistant K562 cells show aberrant protein acetylation and increased sensitivity to histone deacetylase inhibitors. J Pharmacol Exp Ther 2007, 322:1084-1092.
42. Kim J.H., Hahm B., Kim Y.K., Choi M., Jang S.K. Protein-protein interaction among hnRNPs shuttling between nucleus and cytoplasm. J Mol Biol 2000, 298:395-405.
43. Iervolino A., Santilli G., Trotta R., Guerzoni C., Cesi V., Bergamaschi A., et al. hnRNP A1 nucleocytoplasmic shuttling activity is required for normal myelopoiesis and BCR/ABL leukemogenesis. Mol Cell Biol 2002, 22:2255-2266.
44. Notari M., Neviani P., Santhanam R., Blaser B.W., Chang J.S., Galietta A., et al. A MAPK/HNRPK pathway controls BCR/ABL oncogenic potential by regulating MYC mRNA translation. Blood 2006, 107:2507-2516.